Janux Therapeutics 향후 성장

Future 기준 점검 2/6

Janux Therapeutics 의 수익은 연간 9% 감소할 것으로 예상되는 반면, 연간 수익은 63.1% 로 증가할 것으로 예상됩니다. EPS는 연간 6.3% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -26.9% 로 예상됩니다.

핵심 정보

-9.0%

이익 성장률

-6.28%

EPS 성장률

Biotechs 이익 성장	23.0%
매출 성장률	63.1%
향후 자기자본이익률	-26.91%
애널리스트 커버리지	Good
마지막 업데이트	31 Dec 2025

최근 향후 성장 업데이트

Recent updates

Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade)

Dec 02

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Oct 08

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Apr 23

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03

이익 및 매출 성장 예측

NasdaqGM:JANX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	16	-286	-314	-224	11
12/31/2027	3	-251	-261	-169	12
12/31/2026	2	-188	-222	-124	15
12/31/2025	10	-123	-120	-87	15
9/30/2025	10	-102	-71	-70	N/A
6/30/2025	0	-106	-61	-60	N/A
3/31/2025	9	-78	-47	-46	N/A
12/31/2024	11	-69	-44	-44	N/A
9/30/2024	13	-61	-38	-37	N/A
6/30/2024	15	-44	-48	-46	N/A
3/31/2024	7	-56	-53	-52	N/A
12/31/2023	8	-58	-52	-51	N/A
9/30/2023	8	-63	-56	-53	N/A
6/30/2023	8	-68	-60	-54	N/A
3/31/2023	9	-67	-51	-45	N/A
12/31/2022	9	-63	-49	-43	N/A
9/30/2022	7	-60	-47	-41	N/A
6/30/2022	7	-54	-37	-34	N/A
3/31/2022	5	-44	-36	-34	N/A
12/31/2021	4	-33	-18	-17	N/A
9/30/2021	2	-21	-8	-8	N/A
6/30/2021	1	-11	-4	-3	N/A
3/31/2021	0	-8	2	2	N/A
12/31/2020	N/A	-7	-4	-4	N/A

애널리스트 향후 성장 전망

수입 대 저축률: JANX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: JANX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: JANX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: JANX 의 수익(연간 63.1%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: JANX 의 수익(연간 63.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: JANX는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/04 04:06
종가	2026/01/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Janux Therapeutics, Inc.는 22명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Etzer Darout	Barclays
Alec Stranahan	BofA Global Research
Suranjit Mukherjee	BTIG

Janux Therapeutics 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 9.1% to US$63.57

Consensus EPS estimates upgraded to US$1.43 loss, revenue downgraded

Price target increased by 36% to US$37.34

Consensus revenue estimates increase by 37%

Consensus revenue estimates increase by 11%

Consensus revenue estimates fall by 11%

Recent updates

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for Janx007 in Mcrpc

Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade)

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Janux Therapeutics, Inc. Announces Cessation of Chief Strategy Officer, Byron Robinson, Effective September 18, 2025

Janux Therapeutics, Inc. Announces Clinical Milestone Achievement in TRACTr Collaboration with Merck

Janux Therapeutics Highlights Pipeline Progress and Best-In-Class Potential of Novel Bispecific Platform for Autoimmune Diseases At Virtual R&D Day

Janux Therapeutics, Inc. Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Janux Therapeutics, Inc., Annual General Meeting, Jun 11, 2025

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics, Inc. Promotes Zachariah McIver to Chief Medical Officer

Janux Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $349.999727 million.

Janux Therapeutics, Inc. has filed a Follow-on Equity Offering.

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Janux Therapeutics, Inc. Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Janux Therapeutics, Inc. Announces Board Changes

Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Value Index

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Price target increased by 9.1% to US$63.57

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.42 loss in 1Q 2023)

Janux Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Consensus EPS estimates upgraded to US$1.43 loss, revenue downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Janux Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $296.497596 million.

Janux Therapeutics, Inc. Announces Positive Updated Clinical Data for Both of its Clinical Programs

Janux Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Price target increased by 36% to US$37.34

Now 186% overvalued after recent price rise

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo to Chief Scientific Officer

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Consensus revenue estimates increase by 37%

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 11%

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1A Dose Escalation for Psma-Tractr Janx007 and an Update on Pipeline Programs

Now 20% undervalued

Nasdaq Acknowledges Janux Therapeutics’s Non-Compliance with Listing Rule 5605(b)(1)

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Now 23% undervalued after recent price drop

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.3% to US$27.50

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 85%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics, Inc. Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

Consensus revenue estimates increase by 23%

Price target decreased to US$29.67

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

Janux Therapeutics, Inc Appoints Brenda Van Vreeswyk as Head of Human Resources

Janux Therapeutics Appoints Winston Kung to Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 2000 Growth Index

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth